

7th February, 2020

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Press Release

Dear Sir/Madam,

Please find enclosed press release dated 7th February, 2020, regarding acquisition of 4 key brands from Wanbury.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited



Rajendra Chopra
Company Secretary



Encl: as above

Prepared by: Sneha Raheja

Cipla Expands Women's Health Portfolio through Acquisition of 4 Key Brands from Wanbury

Mumbai, India; February 07, 2020: Cipla Ltd. (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") today announced the acquisition of nutrition products' portfolio from Wanbury Ltd. Cipla has acquired 4 brands — CPink, CDense, Productiv and Foline to further strengthen its presence in women's health.

The nutraceutical products, to be sold under the 4 umbrella brands, would address various health needs for conditions arising due to nutritional deficiencies or insufficiencies. This includes supplements such as multivitamins, multimineral and antioxidants for adolescent girls, pregnant and lactating women, women going through menopause and for male and female reproductive health.

Nikhil Chopra, Head India Business, Cipla Limited, said: "We are focused on strengthening our play in the women's health segment by amplifying our four-decade long presence in this category. Through this newly acquired portfolio, we shall be catering to a wide range of patient needs including nutritional deficiencies, bone health and sexual health".

As per (IQVIA MAT Dec'19), the above molecules previously commercialized by Wanbury Ltd have a market size of INR 3,100 Cr in India with sales value of INR 59.6 Cr.

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Dec'19), 3rd largest in the pharma private market in South Africa (IQVIA MAT Dec'19), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and



deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit [Cipla](#), or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

Corporate Communications

Heena Kanal

E-Mail: CorpComm@cipla.com

Investor Relations

Naveen Bansal

E-Mail: Investor.Relations@cipla.com